Clinical Significance of Serum-Derived Exosomal LINC00917 in Patients With Non-Small Cell Lung Cancer

Dani Xiong, Chuanlin Wang, Zhaohui Yang, Fusen Han and Huaibing Zhan *

Department of Respiratory Disease, Qingdao Huangdao District Central Hospital, Qingdao, China

Background: In this study, we aimed to explore the diagnostic potential of serum-based exosomal long intergenic noncoding RNA 917 (LINC00917) in non-small cell lung cancer (NSCLC).

Methods: Exosomes were extracted from NSCLC patients’ serum samples. Exosomal LINC00917 expression levels were compared, by qRT-PCR, between cancer patients and healthy controls, as well as sub-populations of cancer patients. The association between exosomal LINC00917 expression and NSCLC patients’ clinicopathologic factors were investigated, and receiver operating characteristic (ROC) curves were drawn. In addition, NSCLC patients’ overall survivals (OSs) was examined based on exosomal LINC00917 expression and further evaluated by the cox regression analysis.

Results: Serum-derived exosomal LINC00917 was highly expressed in NSCLC patients, and further upregulated in stage III/IV cancer patients. Exosomal LINC00917 yielded modestly good under the curve (AUC) values. Upregulated exosomal LINC00917 expression was closely associated with cancer patients’ advanced stages and shorter OSs.

Conclusion: Serum-derived exosomal LINC00917 may hold diagnostic potential for patients with non-small cell lung cancer.

Keywords: lung cancer, NSCLC, exosome, biomarker, lncRNA

INTRODUCTION

Lung cancer is the leading cause of cancer death among male patients and second leading cause of mortality among female patients in the world (Sung et al., 2021). In the United States of America, although the total cases of lung cancer declined from 2018 to 2020, lung cancer still caused more deaths than breast, prostate, colorectal, and brain cancers combined (Siegel et al., 2020). In China, lung cancer is poised as a heavy burden to public health as it ranks the first in male cancer incidence spectrum (24.17%) and the second in females (15.02%) (He et al., 2020). The most common lung cancer is non-small cell lung cancer (NSCLC), which accounts for ~85% of total lung cancer cases and has diverse pathological features (Chen et al., 2014). It is critical to find suitable biomarkers for NSCLC, so cancer patients can be diagnosed and treated efficiently.

Exosomes are membrane-bound extracellular vesicles that contain secreted proteins, DNAs or RNAs, and then taken up by adjacent cells to affect their functions (Butler, 2002; Peterson et al., 2015). Emerging evidence has indicated that exosomes regulated intercellular communications among cancer cells and their adjacent microenvironments, thus contributing to various aspects of
cancer (NSCLC) between June 2019 and April 2021 were enrolled in this study. Correspondingly, a total of 104 baseline-matched healthy control patients were selected. For all enrolled participants, clinical records were reviewed by two independent physicians, to ensure that nobody underwent major surgeries, chemotherapies radiotherapies or immunotherapies within 180 days prior to the onset of the study. In addition, NSCLC Patients’ staging was categorized in accordance with the seventh edition of AJCC staging guideline (Edge and Compton, 2010).

**Exosomal RNA Extraction and Quantitative Real-Time PCR**

Venous blood samples were drawn from all participants and serum was separated using the two-step centrifugation method. Serum supernatant was processed using a Total Exosome Isolation Reagent (from serum) (Thermo Fisher Scientific, Shanghai, China) to extract exosomes. The exosomal pellets were suspended in phosphate-buffered saline (PBS, Thermo Fisher Scientific, Shanghai, China), and then processed using a Total Exosome RNA & Protein Isolation Kit (Thermo Fisher Scientific, Shanghai, China) to obtain exosomal RNA. Reverse transcription was conducted using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Shanghai, China) according to the manufacturer’s recommendation. Quantitative real-time PCR (qRT-PCR) was performed using a QuantStudio™3 Real Time PCR System (Thermo Fisher Scientific, Shanghai, China). A Made-To-Order LINC00917 TaqMan Noncoding RNA assay (Thermo Fisher Scientific, Shanghai, China) was used to detect exosomal LINC00917 expression. Relative expression levels were quantified using the 2−ΔΔCt algorithm.

**Statistical Analysis**

All statistical analyses were conducted using R Data Analysis App [4.0.3 GUI 1.73 Catalina build (7892)] (https://www.r-project.org/). Quantitative comparisons of exosomal LINC00917 expression levels were conducted using a Wilcoxon Rank Sum Test if there were two patient groups, whereas a Kruskal-Wallis Rank Sum Test was used if there were three or more patient groups. A pROC package (https://cran.r-project.org/web/packages/pROC/pROC.pdf) was used to draw Receiver operating characteristic (ROC) curves and calculate area under the curve (AUC). A Chi-squared test was used to analyze the significances of associating exosomal LINC00917 expression level with NSCLC patients’ clinicopathological factors. A survival package (https://cran.r-project.org/web/packages/survival/survival.pdf) was used to analyze NSCLC patients’ overall survival (OS), and a Kaplan–Meier method with log-rank was performed to compare OSs between different patient groups. Finally, univariate and multivariate cox regression models were conducted to analyze the independence of using exosomal LINC00917 level to predict NSCLC patients’ OS. For all analyses, differences with p values < 0.05 were termed as statistically significant.

**MATERIALS AND METHODS**

**Ethics Statement**

All clinical and experimental procedures were reviewed and approved by the Human Study Ethics Committees at the Qingdao Huangdao District Central Hospital in Qingdao City, Shandong Province, China. Informal consent forms were signed by all participating patients prior to the onset of the study. All protocols were performed in accordance with the Declaration of Helsinki (World Medical Association, 2014).

**NSCLC Patients**

A total of 179 patients diagnosed with non-small cell lung cancer (NSCLC) between June 2019 and April 2021 were enrolled in this study. Correspondingly, a total of 104 baseline-matched healthy control patients were selected. For all enrolled participants, clinical records were reviewed by two independent physicians, to ensure that nobody underwent major surgeries, chemotherapies radiotherapies or immunotherapies within 180 days prior to the onset of the study. In addition, NSCLC Patients’ staging was categorized in accordance with the seventh edition of AJCC staging guideline (Edge and Compton, 2010).

**Exosomal RNA Extraction and Quantitative Real-Time PCR**

Venous blood samples were drawn from all participants and serum was separated using the two-step centrifugation method. Serum supernatant was processed using a Total Exosome Isolation Reagent (from serum) (Thermo Fisher Scientific, Shanghai, China) to extract exosomes. The exosomal pellets were suspended in phosphate-buffered saline (PBS, Thermo Fisher Scientific, Shanghai, China), and then processed using a Total Exosome RNA & Protein Isolation Kit (Thermo Fisher Scientific, Shanghai, China) to obtain exosomal RNA. Reverse transcription was conducted using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Shanghai, China) according to the manufacturer’s recommendation. Quantitative real-time PCR (qRT-PCR) was performed using a QuantStudio™3 Real Time PCR System (Thermo Fisher Scientific, Shanghai, China). A Made-To-Order LINC00917 TaqMan Noncoding RNA assay (Thermo Fisher Scientific, Shanghai, China) was used to detect exosomal LINC00917 expression. Relative expression levels were quantified using the 2−ΔΔCt algorithm.

**Statistical Analysis**

All statistical analyses were conducted using R Data Analysis App [4.0.3 GUI 1.73 Catalina build (7892)] (https://www.r-project.org/). Quantitative comparisons of exosomal LINC00917 expression levels were conducted using a Wilcoxon Ran Sum Test if there were two patient groups, whereas a Kruskal-Wallis Rank Sum Test was used if there were three or more patient groups. A pROC package (https://cran.r-project.org/web/packages/pROC/pROC.pdf) was used to draw Receiver operating characteristic (ROC) curves and calculate area under the curve (AUC). A Chi-squared test was used to analyze the significances of associating exosomal LINC00917 expression level with NSCLC patients’ clinicopathological factors. A survival package (https://cran.r-project.org/web/packages/survival/survival.pdf) was used to analyze NSCLC patients’ overall survival (OS), and a Kaplan–Meier method with log-rank was performed to compare OSs between different patient groups. Finally, univariate and multivariate cox regression models were conducted to analyze the independence of using exosomal LINC00917 level to predict NSCLC patients’ OS. For all analyses, differences with p values < 0.05 were termed as statistically significant.
RESULTS

Exosomal LINC00917 was Upregulated in NSCLC Patients

Exosomal LINC00917 expression levels were compared between NSCLC patients and healthy controls. qRT-PCR analysis showed that, exosomal LINC00917 was significantly upregulated in NSCLC patients than in healthy control patients (Figure 1, p < 0.001).

Exosomal LINC00917 was Upregulated in Stage III/IV NSCLC Patients

Exosomal LINC00917 expression levels were also compared among NSCLC patient sub-populations. qRT-PCR analysis showed that, exosomal LINC00917 expression levels were undifferentiated between patients aged 65 and older, and those younger (Figure 2A, p = 0.6263); between male and female patients (Figure 2B, p = 0.6842); among patients who were non-smokers, current-smokers or formal-smokers (Figure 2C, p = 0.3223), among patients diagnosed with squamous-cell-, adeno- or large-cell- carcinomas (Figure 2D, p = 0.5188), or between patients diagnosed with either positive or negative lymph-node metastasis (Figure 2F, p = 0.1935).

On the other hand, we discovered that exosomal LINC00917 was significantly upregulated in stage III/IV NSCLC patients than in stage I/II NSCLC patients (Figure 2E, p = 0.001).

Exosomal LINC00917 was Associated With NSCLC Clinical Stages

Based on the mean value of NSCLC patients’ exosomal LINC00917 expression levels, cancer patients were dichotomized into two sub-groups. In one group, patients (n = 96) had low exosomal LINC00917 expression levels. In the other group, patients (n = 83) had high exosomal LINC00917 expression levels. Then, the association between NSCLC patients’ clinicopathological factors and dichotomized exosomal LINC00917 expressions were analyzed using a Chi-squared test (Table 1, *p < 0.05). It demonstrated that, low or high exosomal LINC00917 distribution were undifferentiated between patients aged 65 and older, and those younger; between male and female patients; among patients who were non-smokers, current-smokers and formal-smokers, among patients diagnosed with squamous-cell-, adeno- or large-cell- carcinomas, or between patients diagnosed with either positive or negative lymph-node metastasis. However, our analysis indicated that, low or high exosomal LINC00917 distribution was significantly associated with patients’ clinical stages (I/II vs. III/IV) (Table 1, *p = 0.0055).

Exosomal LINC00917 had Good AUC Values for NSCLC

To evaluate the biomarker potential of exosomal LINC00917 for NSCLC, receiver operating characteristic (ROC) curves were drawn. It showed that, areas under the curve (AUC) were 0.811 for all NSCLC patients (Figure 3A), 0.773 for Stage I/II NSCLC patients (Figure 3B) and 0.907 for Stage III/IV NSCLC patients (Figure 3C).

Exosomal LINC00917 was Correlated With Overall Survivals of NSCLC Patients

Finally, we looked into the correlation between exosomal LINC00917 expressions and the overall survivals (OSs) of NSCLC patients. Our data demonstrated that, high expression levels of exosomal LINC00917 were markedly correlated with shorter OSs of all participating NSCLC patients (Figure 4A, p = 0.001), and Stage III/IV NSCLC patients (Figure 4C, p = 0.01). On the other hand, exosomal LINC00917 expression level was undifferentiated for OSs of Stage I/II NSCLC patients (Figure 4B, p = 0.1).

The independence of using exosomal LINC00917 expression level to predict NSCLC patients’ OSs was further examined by cox regression models (Table 2). Based on univariate analysis, we found NSCLC patients’ OS were markedly correlated with tumor clinical stages [p = 0.0395, HR = 1.732, 95% CI (1.027–2.921)], tumor lymph-node metastasis [p = 0.0074, HR = 2.29, 95% CI (1.249–4.2)], as well as exosomal LINC00917 expression level [p = 0.0016, HR = 2.227, 95% CI (1.352–3.669)]. Furthermore, multivariate analysis confirmed that tumor lymph-node metastasis [p = 0.0025, HR = 2.547, 95% CI (1.389–4.669)] and exosomal LINC00917 expression level [p = 0.0038, HR = 2.115, 95% CI (1.273–3.514)] may act as independent factors to predict NSCLC patients’ OS.

DISCUSSIONS

Exosomal proteins or RNAs have emerged as promising non-invasive candidates for cancer prognostic factors (Jia et al., 2017;
In NSCLC, a proteomic study identified urinary exosomal leucine-rich α-2-glycoprotein (LRG1) as a potential diagnosis biomarker (Li et al., 2011). A study on NSCLC patients’ serum exosomes demonstrated that high expression level of exosomal programmed cell-death ligand 1 (PD-L1) was closely associated with cancer patients’ advanced tumor stage, larger tumor size and positive metastasis (Li et al., 2019). In addition, human mature microRNA-425-3p (miR-425-3p) was found to be a potent biomarker for predicting platinum-based chemotherapy responses among NSCLC patients, and had functional role in regulating cancer cell autophagic levels (Yuwen et al., 2019). Thus, the major focus of this study was to explore serum-based exosomal RNAs in NSCLC patients, in order to identify potential non-invasive biomarkers for cancer diagnosis.

LINC00917 was a relatively new epigenetic transcript, that the understandings on its expression and functional roles in human disease are very limited (Chen et al., 2015; Deming et al., 2016).
TABLE 1 | Association between NSCLC patients’ clinicopathological factors and their dichotomized exosomal LINC00917 expressions (*p < 0.05).

| Clinicopathological factors | Patients with low exosomal LINC00917 | Patients with high exosomal LINC00917 |
|-----------------------------|---------------------------------------|----------------------------------------|
|                            | Patient # (%) 96                      | Patient # (%) 83                       | p value |
| Age (years)                 |                                       |                                       |         |
| <65                         | 26 (27.08%)                           | 23 (27.71%)                           | 0.8971  |
| ≥65                         | 70 (72.92%)                           | 60 (72.29%)                           |         |
| Sex                         |                                       |                                       |         |
| M                           | 72 (75.00%)                           | 66 (79.52%)                           | 0.5899  |
| F                           | 24 (25.00%)                           | 17 (20.48%)                           |         |
| Smoker or not               |                                       |                                       |         |
| None                        | 33 (34.38%)                           | 22 (26.51%)                           | 0.2817  |
| Current                     | 48 (50.00%)                           | 41 (49.40%)                           |         |
| Formal                      | 15 (15.62%)                           | 20 (24.09%)                           |         |
| Tumor Subtypes              |                                       |                                       |         |
| squamous-cell carcinoma     | 26 (27.08%)                           | 20 (24.10%)                           |         |
| Adenocarcinoma              | 43 (44.79%)                           | 43 (51.81%)                           | 0.6422  |
| Large-cell carcinoma        | 27 (28.12%)                           | 20 (24.09%)                           |         |
| Tumor Clinical Stages       |                                       |                                       |         |
| I/II                        | 78 (81.25%)                           | 51 (61.45%)                           | 0.0055* |
| III/IV                      | 18 (18.75%)                           | 32 (38.55%)                           |         |
| Tumor Lymph-node metastasis |                                       |                                       |         |
| Positive                    | 65 (67.71%)                           | 61 (73.49%)                           | 0.4966  |
| Negative                    | 31 (32.29%)                           | 22 (26.51%)                           |         |

FIGURE 3 | ROC for exosomal LINC00917 expression among NSCLC patient. Receiver operating characteristic (ROC) curves were drawn, and areas under the curves (AUCs) were calculated while using exosomal LINC00917 expressions to predict NSCLC (A), stage I/II NSCLC (B), and stage III/IV NSCLC (C).
Just recently, Fattahi and colleagues identified that LINC00917 was among the genetic cluster which was aberrantly upregulated in human colorectal tumors (Fattahi et al., 2019). However, the expression of LINC00917 and its potential clinical implications in other human cancers are poorly explored. Thus, in the present study, we first isolated serum exosomes and examined exosomal LINC00917 expressions in NSCLC patients. We discovered that exosomal LINC00917 was significantly upregulated in NSCLC patients’ serum samples than in healthy controls’ serum samples. The upregulation pattern of LINC00917 was in line with the discovery in human colorectal cancer (Fattahi et al., 2019). It would be interestingly to see whether LINC00917 is also upregulated in NSCLC patients’ in situ tumor, which would provide further evidence to identify the origin of LINC00917 upregulation among NSCLC patients.

Second in the present study, exosomal LINC00917 expression levels were compared among NSCLC sub-populations. Based on current data, we did not observe differentiated exosomal LINC00917 expressions among most of the NSCLC sub-populations. However, we did find that exosomal LINC00917 was much more upregulated in NSCLC patients with advanced tumors (Stage III/IV), than in patients with early-staged tumors (Stage I/II). Future clinical studies with expended patient pools would undoubtedly further define the correlation between

FIGURE 4 | Overall survival analysis for exosomal LINC00917 expression among NSCLC patient. The overall survival (OS) curves were drawn, based on dichotomized exosomal LINC00917 expression levels, for all NSCLC patients (A), stage I/II NSCLC patients (B), and stage III/IV NSCLC patients (C).

TABLE 2 | Univariate and multivariate cox regression analyses on the correlations between NSCLC Patients’ clinicopathological factors and overall survival (OS) (Abbreviations: HR, hazard ratio; CI, confidence interval) (*p < 0.05).

| Clinicopathological factors | Comparison | Univariate analysis | Multivariate analysis |
|----------------------------|------------|---------------------|----------------------|
|                            |            | p value             | HR (95%CI)           | p value             | HR (95%CI)           |
| Age (years)                | <65 vs. ≥65| 0.567               | 0.8556 (0.5014–1.46) | —                   | —                   |
| Sex                        | Male vs. Female | 0.652               | 0.8692 (0.4726–1.599) | —                   | —                   |
| Smoker or not              | None vs. (Current and Formal) | 0.135               | 1.555 (0.8713–2.776) | —                   | —                   |
| Tumor subtypes             | Adeno- vs. (Squamous-cell and Large cell) | 0.810               | 1.062 (0.6519–1.73) | —                   | —                   |
| Tumor Clinical Stages      | I/II vs. III/IV | 0.0395*             | 1.732 (1.027–2.921) | 0.0073*             | 1.634 (0.9547–2.796) |
| Tumor lymph-node Metastasis| Positive vs. Negative | 0.0074*             | 2.29 (1.249–4.2) | 0.0025*             | 2.547 (1.3891–4.669) |
| Exosomal LINC00917 level  | Low and High | 0.0016*             | 2.227 (1.352–3.669) | 0.0038*             | 2.115 (1.2732–3.514) |
exosomal LINC00917 expression and NSCLC patients’ clinicopathological factors.

Third in the present study, we discovered that exosomal LINC00917 can be a potential diagnostic biomarker of NSCLC. ROC measurement showed exosomal LINC00917 had fairly good AUC values to differentiate NSCLC patients from healthy controls. Specifically, AUC for Stage III/IV NSCLC patients was 0.907, a very good measurement as compared to other serum-based NSCLC biomarkers, such as CYFRA21-1, CA-125 or Carcinoembryonic antigen (CEA) (Cédrés et al., 2011; Grunnet and Sorensen, 2012). In addition, survival assessment supported our hypothesis, showing that high expression level of exosomal LINC00917 was significantly associated with shorter OSs among all participating NSCLC patients, as well as stage III/IV NSCLC patients. Furthermore, cox regression model demonstrated that serum-based exosomal LINC00917 may act as a potential NSCLC diagnostic biomarker.

While the results of our study are encouraging, drawing a conclusive statement of exosomal LINC00917 being a non-invasive NSCLC biomarker may be premature as certain limitations are associated with our study. First, the numbers of participating NSCLC patients and baseline-matched healthy controls were relatively limited. A multi-Province multi-center cohort study with larger patient population is needed to validate the findings in our study. Second, further clinical investigation, such as examining NSCLC patients’ in situ tumors, is needed to specify the origin of exosomal LINC00917 and verify its association with cancer patients’ prognosis. Furthermore, genetic and biochemical approaches are necessary to reveal the possible functional roles of LINC00917 in regulating NSCLC tumor carcinogenesis and development.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Human Study Ethics Committees at the Qingdao Huangdao District Central Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Conceptualization: HZ Methodology: DX and HZ Validation: HZ Formal analysis and investigation: CW, ZY, and FH Writing—original draft preparation: DX Writing-review and editing: HZ Resources: HZ: Supervision: HZ.

REFERENCES

Bhan, A., Soleimani, M., and Mandal, S. S. (2017). Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 77 (15), 3965–3981. doi:10.1158/0008-5472.can-16-2634
Butler, J. S. (2002). The Yin and Yang of the Exosome. Trends Cell Biol. 12 (2), 90–96. doi:10.1016/s0962-8924(01)02225-5
Cédrés, S., Nuñez, I., Longo, M., Martínez, P., Checa, E., Torrejón, D., et al. (2011). Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis in Advanced Non-small-cell Lung Cancer (NSCLC). Clin. Lung Cancer 12 (3), 172–179. doi:10.1016/j.clc.2011.03.019
Chen, F., Wang, N., Tan, H.-Y., Guo, W., Zhang, C., and Feng, Y. (2019). The Functional Roles of Exosomes-Derived Long Non-coding RNA in Human Cancer. Cancer Biol. Ther. 20 (5), 583–592. doi:10.1080/15384047.2018.1564562
Chen, X., and Yan, G.-Y. (2013). Novel Human IncRNA-Disease Association Inference Based on IncRNA Expression Profiles. Bioinformatics 29 (20), 2617–2624. doi:10.1093/bioinformatics/btt426
Chen, Y., Ni, H., Zhao, Y., Chen, K., Li, M., Li, C., et al. (2015). Potential Role of IncRNAs in Contributing to Pathogenesis of Intervertebral Disc Degeneration Based on Microarray Data. Med. Sci. Monit. 21, 3449–3458. doi:10.12659/mss.894638
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., and Wong, K.-K. (2014). LncRNAs in Contributing to Pathogenesis of Intervertebral Disc Degeneration Based on Microarray Data. Med. Sci. Monit. 20 (7), 3459–3465. doi:10.12659/msm.894638
Dening, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., et al. (2016). A Potential Endophenotype for Alzheimer’s Disease: Cerebrospinal Fluid Clusterin. Neurobiol. Aging 37, 208 e201-e9. doi:10.1016/j.neurobiolaging.2015.09.009
Edge, S. B., and Compton, C. C. (2010). The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 17 (6), 1471–1474. doi:10.1245/s10434-010-0985-3
Fattahi, F., Kiani, J., Khosravi, M., Valaei, S., Mohammadi, A., Majidz, Z., et al. (2019). Enrichment of Up-Regulated and Down-Regulated Gene Clusters Using Gene Ontology, miRNAs and IncRNAs in Colorectal Cancer. Cchts 22 (8), 534–545. doi:10.2174/1386207321666191010114149
Grunnet, M., and Sorensen, J. B. (2012). Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer. Lung Cancer 76 (2), 138–143. doi:10.1016/j.lungcan.2011.11.012
He, S., Li, H., Li, H., Cao, M., Sun, D., Lei, L., et al. (2020). Trends and Risk Factors of Lung Cancer in China. Chin. J. Cancer Res. 32 (6), 683–694. doi:10.21147/jissn.1000-9604.2020.06.02
Jarroux, J., Morillon, A., and Pinskaya, M. (2017). History, Discovery, and Classification of IncRNAs. Adv. Exp. Med. Biol. 1008, 1–46. doi:10.1007/978-981-10-5203-3_1
Jia, Y., Chen, Y., Wang, Q., Jayasinghe, U., Luo, X., Wei, Q., et al. (2017). Exosome: Emerging Biomarker in Breast Cancer. Oncotarget 8 (25), 41717–41733. doi:10.18632/oncotarget.16684
Kazimiernczyk, M., Kasprzowicz, M. K., Kasprzyk, M. E., and Wrzesinski, J. (2020). Human Long Noncoding RNA Interactome: Detection, Characterization and Function. Int. J. Mol. Sci. 21 (3). doi:10.3390/ijms21031027
Kelemen, E., Danis, J., Góbloš, A., Bata-Csongó, Z., and Szell, M. (2019). Exosomal Long Non-coding RNAs as Biomarkers in Human Diseases. EJIFCC 30 (2), 224–236.
Kok, V. C., and Yu, C.-C. (2020). Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development. Jpn Vol. 15, 8019–8036. doi:10.2147/jif2.138273
Leblé, V. S., and Kalluri, R. (2020). Exosomes as a Multicomponent Biomarker Platform in Cancer. Trends Cancer 6 (9), 767–774. doi:10.1016/j.trecan.2020.03.007
Li, C., Li, C., Zhi, C., Liang, W., Wang, X., Chen, X., et al. (2019). Clinical Significance of PD-L1 Expression in Serum-Derived Exosomes in NSCLC Patients. J. Transl Med. 17 (1), 355. doi:10.1186/s12967-019-2101-2
Li, W., Li, C., Zhou, T., Liu, X., Liu, X., Li, X., et al. (2017). Role of Exosomal Proteins in Cancer Diagnosis. Mol. Cancer 16 (1), 145. doi:10.1186/s12943-017-0706-8
Li, Y., Zhang, Y., Qiu, F., and Qiu, Z. (2011). Proteomic Identification of Exosomal LRG1: a Potential Urinary Biomarker for Detecting NSCLC. Electrophoresis 32 (15), 1976–1983. doi:10.1002/elps.201000598
